Pharmaceutical Executive: July/August 2024

Click the title above for a link to open the Pharmaceutical Executive July/August 2024 issue in an interactive PDF format.

Three pieces of coverage in this month’s issue of Pharmaceutical Executive explore the tipping point that's seemingly on the cusp in artificial intelligence.

Pharm Exec’s latest sampling of notable biopharma brand approvals and launches all have unique stories to tell—from the winding journeys to innovative “firsts” to new momentum for milestones to come.

Surviving a long road, novel next-generation treatment offers hope for major depressive disorder.

Key approval signals progress in addressing immune-mediated inflammatory diseases.

A breakthrough for biomarker-altered breast cancer—but broader challenges remain.

New cardiovascular indication builds on treatment’s fast-growing legacy.

Launch campaign ramped up for disease-modifying drug that targets rare and fatal form of hypertension.

How drugmakers can reap value from using generative AI in their market-entry strategies and decision-making, including mitigating launch challenges and enhancing the customer conversation.

The importance of pre-approval information exchange (PIE) with payers and other strategic considerations to help navigate today’s market access challenges and regulatory requirements in bringing promising cell and gene therapies to the market.

Ken Keller, CEO of Daiichi Sankyo’s US business, reflects on the trials, triumphs, and lessons learned in steering the transformation of a legacy cardiovascular company into a global leader in oncology—advancing a vision for a reimagined future in cancer treatment.

It’s time to see where artificial intelligence is genuinely being utilized in pharma.

Why pharma needs to focus on improving—not just extending life.

The region is moving to the forefront in integrating therapeutic innovation.

One, tackle by price; the other, tackle with data.

The data may be a catalyst for sector with a now-likely rate pivot looming.